AUNA
NEUTRAL
$5.66
Live
Auna SA · NYSE
Target $8.77
(+55.0%)
$4.47
52W Range
$9.24
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$418.91M
P/E
5.78
ROE
11.4%
Profit margin
4.3%
Debt/Equity
2.06
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
65%
AUNA exhibits a Piotroski F-Score of 6/9, indicating stable financial health, but lacks an Altman Z-Score, limiting distress risk assessment. The stock appears undervalued with a current price of $5.66 versus a Graham Number of $12.0, suggesting defensive fair value, though growth metrics are weak with negative earnings and revenue growth. Profitability margins and ROE are positive, but high debt/equity and declining earnings raise concerns. Analysts recommend a 'buy' with a target price of $8.77, implying upside potential, but recent price volatility and deteriorating fundamentals temper bullishness.
Key Strengths
Piotroski F-Score of 6/9 indicates stable financial health
Attractive valuation with P/E of 5.78 well below sector average of 209.16
Price/Book of 0.87 suggests shares trade below book value
Strong operating margin of 14.83% and gross margin of 38.68%
Analyst consensus supports 'buy' with 7 analysts and target price of $8.77
Key Risks
Debt/Equity ratio of 2.06 is high, increasing financial risk
Current ratio of 0.90 and quick ratio of 0.70 indicate potential liquidity issues
Earnings growth (YoY) down -50.90%, signaling severe profitability deterioration
Revenue growth (YoY) negative at -0.90%, showing top-line stagnation
No Altman Z-Score available, creating uncertainty around bankruptcy risk
AI Fair Value Estimate
Based on comprehensive analysis
$10.0
+76.7% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
46
Moderate
85
30
55
58
0
AI Verdict
Neutral with value appeal but structural risks
Key drivers: Low P/E and Price/Book support value case, High debt and weak growth constrain upside, Stable Piotroski score offsets some risk, Analyst target implies 55% upside
Confidence
70%
Value
85/100
Ref P/E, PEG, Graham Number
Positives
- Graham Number ($12.0) significantly above current price ($5.66)
- P/E of 5.78 is deeply discounted vs sector
- Price/Sales of 0.10 indicates extreme revenue discount
Watchpoints
- Intrinsic Value (Formula) at $6.86 is below current price, conflicting with Graham
Future
30/100
Ref Growth rates
Positives
- Analyst target price implies growth recovery
Watchpoints
- Earnings growth (YoY) down -50.90%
- Revenue growth (YoY) down -0.90%
- Q/Q earnings growth negative at -50.90%
Past
55/100
Ref Historical trends
Positives
- 3 out of last 4 quarters beat EPS estimates
- Average earnings surprise of +65.19% over last 4 quarters
Watchpoints
- Two prior quarters missed estimates by wide margins (-79%, -26.5%)
- 5Y price change down -41.0%, indicating long-term underperformance
Health
58/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 6/9 indicates stable financial footing
Watchpoints
- Debt/Equity of 2.06 is elevated
- Current ratio (0.90) and quick ratio (0.70) below 1.0
- No Altman Z-Score available for distress risk analysis
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength 0/100
- No dividend yield or payout history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$5.66
Analyst Target
$8.77
Upside/Downside
+55.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AUNA and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AUNA
Auna SA
Primary
|
-41.0% | -41.0% | -30.8% | -9.7% | +21.7% | +22.2% |
|
OVID
Ovid Therapeutics Inc.
Peer
|
-27.0% | -11.8% | +865.0% | +67.3% | +41.5% | +6.2% |
|
EBS
Emergent BioSolutions Inc.
Peer
|
-87.5% | -15.3% | +49.5% | -17.6% | -2.2% | -8.8% |
|
AGL
agilon health, inc.
Peer
|
-96.8% | -95.0% | -73.1% | -51.9% | +41.4% | -2.8% |
|
ACRS
Aclaris Therapeutics, Inc.
Peer
|
-85.2% | -56.5% | +126.9% | +81.5% | +4.4% | +15.7% |
AUN
Auna SA
Primary
5Y
-41.0%
3Y
-41.0%
1Y
-30.8%
6M
-9.7%
1M
+21.7%
1W
+22.2%
OVI
Ovid Therapeutics Inc.
Peer
5Y
-27.0%
3Y
-11.8%
1Y
+865.0%
6M
+67.3%
1M
+41.5%
1W
+6.2%
EBS
Emergent BioSolutions Inc.
Peer
5Y
-87.5%
3Y
-15.3%
1Y
+49.5%
6M
-17.6%
1M
-2.2%
1W
-8.8%
AGL
agilon health, inc.
Peer
5Y
-96.8%
3Y
-95.0%
1Y
-73.1%
6M
-51.9%
1M
+41.4%
1W
-2.8%
ACR
Aclaris Therapeutics, Inc.
Peer
5Y
-85.2%
3Y
-56.5%
1Y
+126.9%
6M
+81.5%
1M
+4.4%
1W
+15.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
5.78
Forward P/E
5.64
PEG Ratio
N/A
P/B Ratio
0.87
P/S Ratio
0.1
EV/Revenue
0.92
EV/EBITDA
4.78
Market Cap
$418.91M
Profitability
Profit margins and return metrics
Profit Margin
4.34%
Operating Margin
14.83%
Gross Margin
38.68%
ROE
11.41%
ROA
5.81%
Growth
Revenue and earnings growth rates
Revenue Growth
-0.9%
Earnings Growth
-50.9%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-50.9%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
2.06
High debt
Current Ratio
0.9
Weak
Quick Ratio
0.7
Poor
Cash/Share
$4.39
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-09
$N/A
2025-11-20
$0.21
+15.6% surprise
2025-08-19
$0.33
+132.8% surprise
2025-05-20
$0.19
+47.2% surprise
Healthcare Sector Comparison
Comparing AUNA against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
5.78
This Stock
vs
75.44
Sector Avg
-92.3%
(Discount)
Return on Equity (ROE)
11.41%
This Stock
vs
-88.14%
Sector Avg
-112.9%
(Below Avg)
Profit Margin
4.34%
This Stock
vs
-16.28%
Sector Avg
-126.7%
(Weaker)
Debt to Equity
2.06
This Stock
vs
2.66
Sector Avg
-22.7%
(Less Debt)
Revenue Growth
-0.9%
This Stock
vs
124.04%
Sector Avg
-100.7%
(Slower)
Current Ratio
0.9
This Stock
vs
4.47
Sector Avg
-80.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AUNA
Auna SA
|
NEUTRAL | $418.91M | 5.78 | 11.4% | 4.3% | $5.66 | |
|
OVID
Ovid Therapeutics Inc.
|
NEUTRAL | $416.84M | - | -17.5% | -240.1% | $2.76 | Compare |
|
EBS
Emergent BioSolutions Inc.
|
BEARISH | $414.71M | 8.63 | 10.5% | 7.1% | $8.03 | Compare |
|
AGL
agilon health, inc.
|
BEARISH | $410.85M | - | -73.3% | -5.2% | $0.99 | Compare |
|
ACRS
Aclaris Therapeutics, Inc.
|
BEARISH | $428.65M | - | -50.2% | -% | $3.54 | Compare |
AUNA
Auna SA
NEUTRAL
Mkt Cap
$419M
P/E
5.8
ROE
11.4%
Price
$5.66
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
7 analysts
Jefferies
2026-01-16
Buy
JP Morgan
2025-11-18
Overweight
Neutral
Past News Coverage
Recent headlines mentioning AUNA from our newsroom.
Newest → oldest
No matching news yet.